




Phenacetin-rat-HTPBTK-Consensus, RMSLE=0.431 10² -10 factor(Dose) 10 Concentration (mg/L) 23 250 360 factor(Route) iv · oral 10⁻¹ -10⁻² -0.25 0.50 0.75 0.00 1.00 Time (Days)





Phenacetin-rat-In Vivo Fits, RMSLE=1.25 10² -10 factor(Dose) 10 Concentration (mg/L) 23 250 360 factor(Route) iv · oral 10⁻¹ -10⁻² -0.25 0.50 0.75 0.00 1.00 Time (Days)







Dichloromethane-rat-HTPBTK-OPERA, RMSLE=0.475 10² -30 -Concentration (mg/L) factor(Route) - oral factor(Dose) 10 -125 3 -0.10 0.15 0.00 0.05 0.20 Time (Days)













Trichloroethylene-rat-HTPBTK-InVitro, RMSLE=0.743 10 factor(Route) Concentration (mg/L) oral factor(Dose) 7.6 18 10⁻¹ -0.10 0.00 0.05 0.15 Time (Days)


Trichloroethylene-rat-HTPBTK-OPERA, RMSLE=0.807 10 factor(Route) Concentration (mg/L) oral factor(Dose) 7.6 18 10⁻¹ -0.05 0.10 0.00 0.15 Time (Days)




















































Tetrachloroethylene-rat-HTPBTK-InVitro, RMSLE=0.381 10² -Concentration (mg/L) factor(Route) 10 -- oral factor(Dose) 500 1 -0.0 0.5 1.0 1.5 Time (Days)


Tetrachloroethylene-rat-HTPBTK-OPERA, RMSLE=0.381 10² -Concentration (mg/L) factor(Route) 10 -- oral factor(Dose) 500 1 -0.0 0.5 1.0 1.5 Time (Days)


Tetrachloroethylene-rat-HTPBTK-Consensus, RMSLE=0.381 10² -Concentration (mg/L) factor(Route) 10 -- oral factor(Dose) 500 1 -0.0 0.5 1.0 1.5 Time (Days)







Acrylonitrile-rat-HTPBTK-Consensus, RMSLE=0.323 10² factor(Dose) Concentration (mg/L) 3.4 10 -47 55 84 factor(Route) 1 -10⁻¹ - 0.00 0.01 0.02 0.05 0.03 0.04 Time (Days)










tert-Amyl methyl ether-human-HTPBTK-InVitro, RMSLE=0.297 0.03 -10⁻² factor(Route) Concentration (mg/L) oral 0.003 factor(Dose) 0.0671 0.201 10⁻³ -3e-04 -0.1 0.2 0.4 0.5 0.3 Time (Days)


tert-Amyl methyl ether-human-HTPBTK-OPERA, RMSLE=0.928 0.03 -10⁻² factor(Route) Concentration (mg/L) oral factor(Dose) 0.0671 0.003 -0.201 10⁻³ -3e-04 -0.2 0.1 0.5 0.3 0.4 Time (Days)

tert-Amyl methyl ether-human-HTPBTK-Consensus, RMSLE=0.832 10⁻² factor(Route) Concentration (mg/L) 0.003 oral factor(Dose) 0.0671 0.201 10⁻³ -3e-04 **-**0.1 0.2 0.5 0.3 0.4 Time (Days)


2,4-Dichlorophenoxyacetic acid-rat-HTPBTK-InVitro, RMSLE=0.762 10 factor(Dose) 0.205 1.04 Concentration (mg/L) 1.5 2 3.56 factor(Route) oral 10⁻³ -0.25 0.50 0.75 0.00 1.00 Time (Days)





2,4-Dichlorophenoxyacetic acid-rat-HTPBTK-Dawson, RMSLE=0.736 10 factor(Dose) 0.205 1.04 Concentration (mg/L) 1.5 2 3.56 factor(Route) oral 10⁻³ -0.25 0.50 0.75 0.00 1.00 Time (Days)





 $2,4-Dichlorophenoxyacetic\ acid-rat-HTPBTK-Consensus,\ RMSLE=1.45$ 10 factor(Dose) 0.205 1.04 Concentration (mg/L) 1.5 2 3.56 factor(Route) oral 10⁻³ -0.25 0.50 0.75 0.00 1.00 Time (Days)



























Alprazolam-rat-HTPBTK-ADmet, RMSLE=1.8 10 -1 factor(Dose) Concentration (mg/L) 1.25 12.5 factor(Route) · oral 10⁻² -10⁻³ -0.10 0.05 0.15 0.20 0.25 0.00 Time (Days)








Alprazolam-rat-HTPBTK-OPERA, RMSLE=1.82 10 -1 factor(Dose) Concentration (mg/L) 1.25 12.5 10⁻¹ factor(Route) · oral 10⁻² -10⁻³ -0.10 0.05 0.15 0.20 0.25 0.00 Time (Days)





































































































1-Naphthalenol, 1-(N-methylcarbamate)-rat-In Vivo Fits, RMSLE=0.115 10⁻² factor(Dose) Concentration (mg/L) factor(Route) iv oral 10⁻³ -0.02 0.01 0.03 0.04 Time (Days)


Carbendazim-rat-HTPBTK-InVitro, RMSLE=1.08 10² -10 -Concentration (mg/L) factor(Route) **▶** oral factor(Dose) 1000 1 -10⁻¹ -0.0 0.2 0.4 0.6 0.8 Time (Days)











Carbendazim-rat-HTPBTK-OPERA, RMSLE=1.08 10² -10-Concentration (mg/L) factor(Route) oral factor(Dose) 1000 1 -10⁻¹ -0.0 0.2 0.4 0.6 0.8 Time (Days)


























































































Fenarimol-rat-HTPBTK-Dawson, RMSLE=1.29 1 factor(Dose) Concentration (mg/L) 0.4 2 factor(Route) iv oral 10⁻² -0.1 0.2 0.3 0.4 0.0 0.5 Time (Days)











Fenarimol-rat-In Vivo Fits, RMSLE=0.24 10⁻¹ factor(Dose) Concentration (mg/L) 0.4 2 0.03 factor(Route) iv oral 10⁻² 0.2 0.4 0.1 0.3 0.0 0.5 Time (Days)




























Formetanate hydrochloride-rat-HTPBTK-Consensus, RMSLE=0.667 0.3 -10⁻¹ factor(Dose) Concentration (mg/L) 0.03 factor(Route) 10⁻² -· oral 0.003 -2 3 0 1 Time (Days)




Ibuprofen-rat-HTPBTK-InVitro, RMSLE=0.788 10² -10 -Concentration (mg/L) factor(Dose) 2.5 25 factor(Route) 10⁻¹ -0.0 0.2 0.6 0.4 Time (Days)

Ibuprofen-rat-HTPBTK-ADmet, RMSLE=0.791 10² -10 factor(Dose) Concentration (mg/L) 2.5 25 factor(Route) 10⁻¹ -0.0 0.2 0.6 0.4 Time (Days)





Ibuprofen-rat-HTPBTK-Pradeep, RMSLE=0.794 10² -10 factor(Dose) Concentration (mg/L) 2.5 25 factor(Route) 10⁻¹ -0.0 0.2 0.6 0.4 Time (Days)


Ibuprofen-rat-HTPBTK-OPERA, RMSLE=0.692 10² -10 -Concentration (mg/L) factor(Dose) 2.5 25 factor(Route) 10⁻¹ -0.0 0.2 0.6 0.4 Time (Days)





Ibuprofen-rat-In Vivo Fits, RMSLE=0.663 10² -10 factor(Dose) Concentration (mg/L) 2.5 25 factor(Route) 10⁻¹ -0.0 0.2 0.4 0.6 Time (Days)
















































Imipramine-rat-HTPBTK-Consensus, RMSLE=1.02 3 factor(Dose) Concentration (mg/L) 10 50 0.3 factor(Route) iv · oral 10⁻¹ -0.03 -0.50 0.25 0.75 0.00 1.00 Time (Days)











Midazolam-rat-HTPBTK-OPERA, RMSLE=1.7 10 factor(Dose) Concentration (mg/L) 5 15 10⁻¹ factor(Route) iv · oral 10⁻² 10⁻³ -0.05 0.10 0.15 0.00 Time (Days)

















Nilvadipine-rat-HTPBTK-OPERA, RMSLE=2 10 -1 factor(Dose) Concentration (mg/L) 0.1 10 factor(Route) iv · oral 10⁻² -10⁻³ -0.0 0.1 0.2 0.3 0.4 Time (Days)










Ondansetron-rat-HTPBTK-ADmet, RMSLE=1.08 10² -10 factor(Route) Concentration (mg/L) · oral factor(Dose) 20 10⁻¹ -0.05 0.10 0.00 0.15 Time (Days)

Ondansetron-rat-HTPBTK-Dawson, RMSLE=1.06 10² -10 factor(Route) Concentration (mg/L) · oral factor(Dose) 20 10⁻¹ -0.05 0.10 0.00 0.15 Time (Days)





Ondansetron-rat-HTPBTK-Consensus, RMSLE=1.05 10² -10 factor(Route) Concentration (mg/L) · oral factor(Dose) 20 10⁻¹ -0.05 0.10 0.00 0.15 Time (Days)





Permethrin-rat-HTPBTK-ADmet, RMSLE=1.58 1 -10⁻¹ factor(Dose) Concentration (mg/L) factor(Route) iv · oral 0.5 0.0 1.0 1.5 2.0 Time (Days)







Permethrin-rat-In Vivo Fits, RMSLE=0.29 10⁻¹ -0.03 factor(Dose) Concentration (mg/L) 10⁻² factor(Route) iv · oral 0.003 -0.5 0.0 1.0 1.5 2.0 Time (Days)


5,5-Diphenylhydantoin-rat-HTPBTK-InVitro, RMSLE=0.738 10² factor(Dose) Concentration (mg/L) 25 40 factor(Route) 10 iv · oral 1 -0.2 0.0 0.1 0.4 0.5 0.3 Time (Days)


5,5-Diphenylhydantoin-rat-HTPBTK-ADmet, RMSLE=0.84 10² factor(Dose) Concentration (mg/L) 25 40 factor(Route) 10 iv · oral 1 -0.2 0.0 0.1 0.4 0.5 0.3 Time (Days)





5,5-Diphenylhydantoin-rat-HTPBTK-OPERA, RMSLE=0.757 10² factor(Dose) Concentration (mg/L) 25 40 factor(Route) 10 iv · oral 1 -0.2 0.0 0.1 0.4 0.5 0.3 Time (Days)





Propamocarb hydrochloride-rat-HTPBTK-InVitro, RMSLE=2.17 1 -10⁻¹ factor(Dose) Concentration (mg/L) 10⁻² factor(Route) iv · oral 10⁻³ -10⁻⁴ -0.02 0.04 0.00 0.06 0.08 Time (Days)


Propamocarb hydrochloride-rat-HTPBTK-ADmet, RMSLE=2.02 10⁻¹ factor(Dose) Concentration (mg/L) 10⁻² factor(Route) iv · oral 10⁻³ -10⁻⁴ -0.02 0.04 0.00 0.06 0.08 Time (Days)


Propamocarb hydrochloride-rat-HTPBTK-Dawson, RMSLE=2.3 1 -10⁻¹ factor(Dose) Concentration (mg/L) 10⁻² factor(Route) iv · oral 10⁻³ -10⁻⁴ -0.02 0.00 0.04 0.06 0.08 Time (Days)


Propamocarb hydrochloride-rat-HTPBTK-Pradeep, RMSLE=2.16 1 -10⁻¹ factor(Dose) Concentration (mg/L) 10⁻² factor(Route) iv · oral 10⁻³ -10⁻⁴ -0.02 0.00 0.04 0.06 0.08 Time (Days)


Propamocarb hydrochloride-rat-HTPBTK-Consensus, RMSLE=2.01 10⁻¹ factor(Dose) Concentration (mg/L) factor(Route) iv · oral 10⁻³ -10⁻⁴ -0.02 0.00 0.04 0.06 0.08 Time (Days)


Propamocarb hydrochloride-rat-In Vivo Fits, RMSLE=0.252 10⁻¹ -10⁻² factor(Dose) Concentration (mg/L) factor(Route) iv oral 10⁻³ -10⁻⁴ -0.02 0.04 0.08 0.00 0.06 Time (Days)


























































S-Bioallethrin-rat-In Vivo Fits, RMSLE=0.254 0.03 factor(Route) Concentration (mg/L) • oral 10⁻² factor(Dose) 0.8 0.003 -10⁻³ -0.1 0.2 0.0 0.3 Time (Days)















Simazine-rat-In Vivo Fits, RMSLE=0.305 10⁻¹ factor(Dose) Concentration (mg/L) 0.4 2 10⁻² factor(Route) iv · oral 10⁻³ -0.10 0.05 0.15 0.00 Time (Days)

Tolbutamide-rat-HTPBTK-InVitro, RMSLE=0.243 50 factor(Dose) Concentration (mg/L) 10 20 factor(Route) iv oral 20 -0.0 0.2 0.1 0.3 0.4 0.5 Time (Days)














Tolbutamide-rat-In Vivo Fits, RMSLE=0.689 300 factor(Dose) Concentration (mg/L) 10 20 10² factor(Route) iv oral 30 -0.1 0.2 0.3 0.4 0.5 0.0 Time (Days)















Valproic acid-rat-HTPBTK-InVitro, RMSLE=0.61 10³ -10² factor(Dose) 10 Concentration (mg/L) 50 100 200 600 10 factor(Route) · oral 1 -0.10 0.05 0.00 0.15 Time (Days)


Valproic acid-rat-HTPBTK-ADmet, RMSLE=0.645 10³ -10² factor(Dose) 10 Concentration (mg/L) 50 100 200 600 10 factor(Route) · oral 1 -0.10 0.05 0.00 0.15 Time (Days)


Valproic acid-rat-HTPBTK-Dawson, RMSLE=0.615 10³ -10² factor(Dose) 10 Concentration (mg/L) 50 100 200 600 10 factor(Route) oral 1 -0.10 0.05 0.00 0.15 Time (Days)





Valproic acid-rat-HTPBTK-OPERA, RMSLE=0.669 10³ -10² factor(Dose) 10 Concentration (mg/L) 50 100 200 600 10 factor(Route) · oral 1 -0.10 0.05 0.00 0.15 Time (Days)


Valproic acid-rat-HTPBTK-Consensus, RMSLE=1.48 10³ -10² factor(Dose) 10 Concentration (mg/L) 50 100 200 600 10 factor(Route) · oral 1 -0.05 0.10 0.15 0.00 Time (Days)































Oxazepam-rat-In Vivo Fits, RMSLE=0.234 10factor(Dose) 20 Concentration (mg/L) 3 **-**50 200 400 factor(Route) · oral 1 -0.3 -0.0 0.3 0.6 0.9 Time (Days)

Pentachlorophenol-rat-HTPBTK-InVitro, RMSLE=0.739 10² factor(Dose) 5 9.5 Concentration (mg/L) 18.8 38 75 150 10 factor(Route) oral 1 -0.5 0.0 1.0 1.5 Time (Days)

Pentachlorophenol-rat-HTPBTK-ADmet, RMSLE=0.725 10² factor(Dose) 5 9.5 Concentration (mg/L) 18.8 38 75 150 10 factor(Route) oral 1 -0.5 0.0 1.0 1.5 Time (Days)





Pentachlorophenol-rat-HTPBTK-OPERA, RMSLE=0.739 10² factor(Dose) 5 9.5 Concentration (mg/L) 18.8 38 75 150 10 factor(Route) oral 1 -0.5 0.0 1.0 1.5 Time (Days)




Pentachlorophenol-rat-In Vivo Fits, RMSLE=0.293 10² factor(Dose) 5 9.5 Concentration (mg/L) 18.8 38 75 150 10 factor(Route) oral 1 -0.5 0.0 1.0 1.5 Time (Days)

Gemfibrozil-rat-HTPBTK-InVitro, RMSLE=0.943 10² -10 factor(Dose) Concentration (mg/L) 4.29 50 100 factor(Route) 1 -· oral 10⁻¹ -0.25 0.50 0.00 0.75 1.00 Time (Days)








Gemfibrozil-rat-HTPBTK-Consensus, RMSLE=0.986 10² -10 factor(Dose) Concentration (mg/L) 4.29 50 100 factor(Route) 1 -· oral 10⁻¹ -0.00 0.25 0.50 0.75 1.00 Time (Days)

Gemfibrozil-rat-In Vivo Fits, RMSLE=0.335 10² -10 factor(Dose) Concentration (mg/L) 4.29 50 100 factor(Route) 1 -· oral 10⁻¹ -0.00 0.25 0.50 0.75 1.00 Time (Days)





Dibutyl 1,2-benzenedicarboxylate-rat-HTPBTK-ADmet, RMSLE=0.474 10-Concentration (mg/L) factor(Dose) 20 factor(Route) iv iv 1 -0.006 0.009 0.012 0.003 Time (Days)


Dibutyl 1,2-benzenedicarboxylate-rat-HTPBTK-Dawson, RMSLE=0.484 10-Concentration (mg/L) factor(Dose) 20 factor(Route) iv 1 -0.006 0.009 0.012 0.003 Time (Days)


Dibutyl 1,2-benzenedicarboxylate-rat-HTPBTK-OPERA, RMSLE=0.478 10-Concentration (mg/L) factor(Dose) 20 factor(Route) iv iv 1 -0.006 0.009 0.012 0.003 Time (Days)


Dibutyl 1,2-benzenedicarboxylate-rat-HTPBTK-Consensus, RMSLE=0.461 10-Concentration (mg/L) factor(Dose) 20 factor(Route) iv iv 1 -0.006 0.009 0.012 0.003 Time (Days)




















Benzophenone-rat-HTPBTK-OPERA, RMSLE=0.889 1 factor(Dose) 2.5 Concentration (mg/L) 10 factor(Route) 10⁻¹ -· oral 10⁻² -0.25 0.50 0.75 1.00 0.00 Time (Days)


Benzophenone-rat-HTPBTK-Consensus, RMSLE=0.733 1 factor(Dose) Concentration (mg/L) 2.5 10 factor(Route) oral 10⁻² -0.25 0.50 0.75 0.00 1.00 Time (Days)

Benzophenone-rat-In Vivo Fits, RMSLE=0.323 1 factor(Dose) Concentration (mg/L) 2.5 10 factor(Route) 10⁻¹ oral 10⁻² -0.25 0.50 0.75 0.00 1.00 Time (Days)


2-Hydroxy-4-methoxybenzophenone-rat-HTPBTK-InVitro, RMSLE=2.78 10² factor(Dose) 8 Concentration (mg/L) 100 250 500 factor(Route) oral 10⁻² -0.2 0.0 0.4 0.6

Time (Days)

2-Hydroxy-4-methoxybenzophenone-rat-HTPBTK-ADmet, RMSLE=2.3



2-Hydroxy-4-methoxybenzophenone-rat-HTPBTK-Dawson, RMSLE=2.57



2-Hydroxy-4-methoxybenzophenone-rat-HTPBTK-Pradeep, RMSLE=2.69 10² factor(Dose) 8 Concentration (mg/L) 100 250 500 factor(Route) oral 10⁻²

0.4

Time (Days)


0.6

0.2


0.0


2-Hydroxy-4-methoxybenzophenone-rat-HTPBTK-OPERA, RMSLE=2.77 10² factor(Dose) 8 Concentration (mg/L) 100 250 500 factor(Route) oral 10⁻² -0.2 0.0 0.4 0.6 Time (Days)


2-Hydroxy-4-methoxybenzophenone-rat-HTPBTK-Consensus, RMSLE=2.08





2-Hydroxy-4-methoxybenzophenone-rat-In Vivo Fits, RMSLE=0.472 10 -1 factor(Dose) 8 Concentration (mg/L) 100 250 500 factor(Route)






















Phenolphthalein-rat-In Vivo Fits, RMSLE=0.386 10² -10 -Concentration (mg/L) factor(Dose) 25 factor(Route) 1 -- iv 10⁻¹ -10⁻² 0.25 0.50 0.75 0.00 1.00 Time (Days)














































Etoxazole-rat-HTPBTK-Consensus, RMSLE=1.92 10⁻¹ factor(Dose) Concentration (mg/L) 0.4 2 10⁻² factor(Route) iv · oral 10⁻³ -10⁻⁴ 2 0 Time (Days)
















Novaluron-rat-In Vivo Fits, RMSLE=0.173 0.3 -10⁻¹ factor(Dose) Concentration (mg/L) 0.4 2 0.03 factor(Route) iv oral 10⁻² -0.003 -2 Ó 3 Time (Days)







































2-Methylimidazole-rat-HTPBTK-OPERA, RMSLE=0.988 10 -Concentration (mg/L) factor(Dose) 10 factor(Route) ⊢ iv 10⁻¹ -5 10 15 20 Time (Days)


 $2-Methylimidazole-rat-HTPBTK-Consensus,\ RMSLE=1.34$ 10 -Concentration (mg/L) factor(Dose) 10 factor(Route) **⊢** iv 10⁻¹ -5 10 15 20 Time (Days)



















Dichloroacetic acid-rat-HTPBTK-ADmet, RMSLE=0.744 10² factor(Route) 10-Concentration (mg/L) · oral factor(Dose) 10 40 60 100 1 -10⁻¹ 0.0 0.1 0.2 0.3 Time (Days)



Dichloroacetic acid-rat-HTPBTK-Consensus, RMSLE=1.12 10 factor(Route) Concentration (mg/L) · oral factor(Dose) 10 40 60 1 -100 10⁻¹ -0.2 0.1 0.3 0.0 Time (Days)



Dibromoacetic acid-rat-HTPBTK-ADmet, RMSLE=0.802 10² factor(Dose) 10 10-25 Concentration (mg/L) 40 50 100 110 125 factor(Route) 1 oral 10⁻¹ -0.0 0.1 0.2 0.3 Time (Days)

Dibromoacetic acid-rat-HTPBTK-Pradeep, RMSLE=0.56 10² factor(Dose) 10 10-25 Concentration (mg/L) 40 50 100 110 125 factor(Route) 1 oral 10⁻¹ -0.0 0.1 0.2 0.3 Time (Days)

Dibromoacetic acid-rat-HTPBTK-Consensus, RMSLE=0.526 10² factor(Dose) 10 10 -25 Concentration (mg/L) 40 50 100 110 125 factor(Route) 1 oral 10⁻¹ -0.2 0.0 0.1 0.3 Time (Days)


Dibromoacetic acid-rat-In Vivo Fits, RMSLE=0.34 10² factor(Dose) 10 10-25 Concentration (mg/L) 40 50 100 110 125 factor(Route) 1 -· oral 10⁻¹ -0.0 0.1 0.2 0.3 Time (Days)


Bromochloroacetic acid-rat-HTPBTK-ADmet, RMSLE=1.01 10² -10 factor(Dose) 10 Concentration (mg/L) 40 80 100 factor(Route) 1 oral 10⁻¹ -0.1 0.0 0.2 0.3 Time (Days)


Bromochloroacetic acid-rat-HTPBTK-Pradeep, RMSLE=0.645 10 factor(Dose) 10 Concentration (mg/L) 40 80 100 factor(Route) oral 10⁻¹ -0.1 0.0 0.2 0.3 Time (Days)

Bromochloroacetic acid-rat-HTPBTK-Consensus, RMSLE=0.898 10 factor(Dose) 10 Concentration (mg/L) 40 80 100 factor(Route) oral 10⁻¹ -0.1 0.0 0.2 0.3 Time (Days)


Bromochloroacetic acid-rat-In Vivo Fits, RMSLE=0.385 10 factor(Dose) 10 Concentration (mg/L) 40 80 100 factor(Route) oral 10⁻¹ -0.1 0.0 0.2 0.3 Time (Days)









 $Bis (2-chloroethoxy) methane-rat-HTPBTK-Consensus,\ RMSLE=0.385$ 10 factor(Dose) Concentration (mg/L) 20 40 factor(Route) 10⁻¹ -10⁻² -0.2 0.3 0.4 0.0 0.1 Time (Days)





Isoeugenol-rat-HTPBTK-Dawson, RMSLE=1.73 10 factor(Dose) Concentration (mg/L) 17 70 140 factor(Route) oral 10⁻¹ -10⁻² 0.0 0.1 0.2 0.3 0.4 Time (Days)





Isoeugenol-rat-HTPBTK-OPERA, RMSLE=1.13 10 factor(Dose) Concentration (mg/L) 17 70 140 factor(Route) oral 10⁻¹ -0.1 0.3 0.0 0.2 0.4 Time (Days)


Isoeugenol-rat-HTPBTK-Consensus, RMSLE=1.18 10 factor(Dose) Concentration (mg/L) 17 70 140 factor(Route) oral 10⁻¹ -0.0 0.1 0.3 0.2 0.4 Time (Days)


Isoeugenol-rat-In Vivo Fits, RMSLE=0.36 10 factor(Dose) Concentration (mg/L) 17 70 140 factor(Route) · oral 10⁻¹ -0.0 0.1 0.2 0.3 0.4 Time (Days)

Emodin-rat-HTPBTK-ADmet, RMSLE=1.81 10² factor(Dose) 10 -Concentration (mg/L) 5 40 80 factor(Route) · oral 1 -10⁻¹ 0.1 0.2 0.3 0.4 0.5 0.0 Time (Days)














Emodin-rat-In Vivo Fits, RMSLE=0.189 10factor(Dose) Concentration (mg/L) 5 40 80 1 factor(Route) · oral 10⁻¹ -0.1 0.2 0.3 0.4 0.5 0.0 Time (Days)














Anthraquinone-rat-HTPBTK-ADmet, RMSLE=1.78 10² -10 factor(Dose) 2 Concentration (mg/L) 40 100 400 factor(Route) oral 10⁻¹ -0.25 0.50 0.75 0.00 1.00 Time (Days)


Anthraquinone-rat-HTPBTK-Dawson, RMSLE=1.53 10² -10factor(Dose) 2 Concentration (mg/L) 40 100 400 factor(Route) · oral 10⁻¹ -0.25 0.50 0.75 0.00 1.00 Time (Days)




Anthraquinone-rat-HTPBTK-Consensus, RMSLE=1.4 10² -10 factor(Dose) 2 Concentration (mg/L) 40 100 400 factor(Route) · oral 10⁻¹ -0.25 0.50 0.75 0.00 1.00 Time (Days)














Oxymetholone-rat-HTPBTK-OPERA, RMSLE=1.09 30 -10factor(Dose) Concentration (mg/L) 20 30 3 -120 factor(Route) oral 1 -0.3 -0.0 0.1 0.2 0.3 0.4 0.5 Time (Days)



































Diclofenac-rat-HTPBTK-OPERA, RMSLE=0.564 10² -30 factor(Dose) Concentration (mg/L) 18 60 factor(Route) 10 iv · oral 3 -0.1 0.2 0.0 0.3 Time (Days)


Diclofenac-rat-HTPBTK-Consensus, RMSLE=0.484 10² -30 factor(Dose) Concentration (mg/L) 18 60 factor(Route) 10 iv · oral 3 -0.1 0.2 0.0 0.3 Time (Days)


Diclofenac-rat-In Vivo Fits, RMSLE=0.482 300 -10² factor(Dose) Concentration (mg/L) 30 -18 60 factor(Route) iv 10-· oral 3 -0.1 0.2 0.0 0.3 Time (Days)











































Thiodiglycolic acid-rat-HTPBTK-Consensus, RMSLE=0.487 30 -10-Concentration (mg/L) factor(Dose) 20 3 factor(Route) iv 1 -0.3 -0.0 0.1 0.2 0.3 0.4 Time (Days)




Oxoacetic acid--water (1/1)-rat-HTPBTK-OPERA, RMSLE=0.711 10² -30 -Concentration (mg/L) factor(Dose) 50 factor(Route) iv 10 -3 -0.005 0.010 0.015 0.020 Time (Days)


Oxoacetic acid--water (1/1)-rat-HTPBTK-Consensus, RMSLE=0.711 10² -30 -Concentration (mg/L) factor(Dose) 50 factor(Route) iv 10 -3 -0.005 0.010 0.015 0.020 Time (Days)


Oxoacetic acid—water (1/1)-rat-In Vivo Fits, RMSLE=0.0752 10² -30 -Concentration (mg/L) factor(Dose) 50 factor(Route) ⊢ iv 10 -3 -0.005 0.010 0.015 0.020 Time (Days)





2-Methyltetrahydrofuran-rat-HTPBTK-Consensus, RMSLE=0.668 10² factor(Dose) 10-2.5 10 Concentration (mg/L) 30 40 100 400 factor(Route) oral 10⁻¹ -10⁻² -0.1 0.2 0.3 0.0 0.4 0.5 Time (Days)
















2,3,7,8-Tetrachlorodibenzo-p-dioxin-rat-HTPBTK-OPERA, RMSLE=0.418 5e-04 **-**Concentration (mg/L) factor(Route) **⊢** oral factor(Dose) 1e-04 10⁻⁴ -5 10 15 0 Time (Days)





Hexachlorobenzene-rat-In Vivo Fits, RMSLE=1.86 10 -1 factor(Route) Concentration (mg/L) · oral factor(Dose) 10⁻¹ 0.03 0.1 0.3 30 10⁻² 10⁻³ -40 60 0 20 80 Time (Days)

Potassium perfluorohexanesulfonate-rat-In Vivo Fits, RMSLE=2.54 10² factor(Dose) 10 -Concentration (mg/L) 16 32 factor(Route) · oral 10⁻¹ -20 0 10 40 50 30 Time (Days)

Potassium perfluorobutanesulfonate-rat-In Vivo Fits, RMSLE=2.46 10² factor(Dose) 10 -Concentration (mg/L) 20 100 factor(Route) · oral 10⁻¹ -0.5 1.0 1.5 2.0 0.0 Time (Days)

